R&D News | pharmaphorum

News

Hope rises for vaccine against hookworm parasite

Pivotal trials are being prepared for the Na-GST 1/Al–CpG vaccine, which could help address a parasite affecting hundreds of millions of people.

News

Alto raises $120m for resistant depression programme

Alto Neuroscience has raised $120m that will fund pivotal trials of its recently acquired candidate for treatment-resistant depression.

News

BioMarin halts Voxzogo trials due to safety signal

BioMarin has suspended dosing in phase 2 trials of its achondroplasia therapy Voxzogo aimed at broadening the drug's label.

News

Roche's AI-powered digital pathology open environment in action

Roche accelerates AI adoption with NVIDIA deal

Roche has ramped up its investment in NVIDIA's AI chips, launching a hybrid-cloud AI factory that it believes is the largest in the pharma industry.

News

Data builds behind Bayer's Kerendia in kidney disease

Bayer's Kerendia has hit the spot in another phase 3 trial that could fuel its already rapid growth as a chronic kidney disease treatment.

News

Yellow balloons with smiling faces drawn on them in black ink

J&J says Inlexzo follow-up 'promising' in bladder cancer

Johnson & Johnson says localised delivery of its FGFR inhibitor erdafitinib could provide the first targeted treatment for early‑stage bladder cancer.

Hope rises for vaccine against hookworm parasite

Alto raises $120m for resistant depression programme

BioMarin halts Voxzogo trials due to safety signal

Roche accelerates AI adoption with NVIDIA deal

Data builds behind Bayer's Kerendia in kidney disease

J&J says Inlexzo follow-up 'promising' in bladder cancer

ESMO26: Bayer's Nubeqa finds new prostate cancer role

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks